不同增敏药物联合放疗治疗恶性肿瘤的临床效果分析  

Efficacy and Safety of Radiotherapy Combined with Different Sensitive Drugs in the Treatment of Malignant Tumors

作　　者：王正安[1] 刘燕青[2] 黄飞[3] 胡鹏飞[4] WANG Zheng＇an LIU Yanqing HUANG Fei HU Pengfei(The Oncology Department, Loudi Central Hospital, Loudi, Hunan, 417000, China The Otolaryngology Head and Neck Surgery Department 4 the Physician Department, the First People＇s Hospital of Jingzhou, Jingzhou, Hubei, 434000, China 3 The Infectioas Disease Department, Jingzhou Central Hospital, Jingzhou, Hubei, 434020, China)

机构地区：[1]娄底市中心医院肿瘤科,湖南娄底417000 [2]荆州市第一人民医院耳鼻咽喉头颈外科,湖北荆州434000 [3]荆州市中心医院感染科,湖北荆州434020 [4]荆州市第一人民医院内科,湖北荆州434000

出　　处：《肿瘤药学》2017年第3期364-369,379,共7页Anti-Tumor Pharmacy

摘　　要：目的分析不同增敏药物联合放疗治疗恶性肿瘤的疗效与安全性。方法选取120例符合放疗指征的癌症早期患者为研究对象,随机均分为放疗组、增敏1组、增敏2组及增敏3组,每组各30例,放疗组行常规放射治疗,增敏1组在放疗组的基础上给予硝基咪唑类药物,增敏2组在放疗组的基础上给予环氧化酶2型抑制类药物,增敏3组在放疗组的基础上给予HIF1型抑制类药物。评估各组的临床疗效,血清C反应蛋白及肿瘤标志物的变化,不良反应的发生情况以及治疗后1年的生活质量。结果增敏3组临床治愈率为63.33%,总有效率为93.33%;增敏2组临床治愈率为30.00%,总有效率为73.33%;增敏1组临床治愈率为46.67%,总有效率为80.00%;放疗组临床治愈率为23.33%,总有效率为60.00%;各组临床疗效比较,差异有统计学意义(P<0.01),增敏3组临床疗效优于放疗组与增敏2组(P<0.01),增敏1组临床疗效优于放疗组(P<0.05)。放疗组不良反应发生情况与增敏1组、增敏3组比较,差异无统计学意义(P>0.05);增敏2组一般不良反应与消化系统不良反应发生情况优于放疗组(P<0.05)。治疗后各组血清CRP和CEA表达水平的差异有统计学意义(P<0.01),增敏3组CRP和CEA表达水平最低,放疗组显著高于各增敏组(P<0.01),增敏2组明显高于增敏3组(P<0.05)。随访1年后,各组QLQ-C30评分差异有统计学意义(P<0.01),增敏各组QLQ-C30评分显著高于放疗组(P<0.01),增敏2组明显低于增敏3组(P<0.05)。结论放疗联合增敏药物可有效提高恶性肿瘤的临床疗效,且用药安全。Objective To investigate the efficacy and safety of different sensitizing drugs combined with radiotherapy in the treatment of malignant tumor. Methods 120 cases of cancer patients in early stage with radiotherapy indications were included as the research objects. They were randomly divided into radiotherapy group, sensitization group 1, 2 and 3, with 30 cases in each group. Patients in radiotherapy group received conventional radiotherapy. Those in radiotherapy sensitization group 1 were given nitroimidazole treatment, and in sensitiza- tion group 2 cyclooxygenase 2 inhibitor drugs, and in sensitization group 3 HIF1 inhibitors, on the basis of radiotherapy group. Evaluate the clinical efficacy, changes of serum C reactive protein and tumor markers, adverse reactions and quality of life within one year after treatment. Results The clinical cure rate was 63.33% and the total effective rate was 93.33% in the sensitization group 3. The clinical cure rate of sen- sitization group 1 was 46.67% and the total effective rate was 80.00%. The clinical cure rate of sensitization group 2 was 30.00% and the effective rate was 73.33%. In the radiotherapy group, the clinical cure rate was 23.33%, and the total effective rate was 60.00%. There were statistically significant differences in clinical efficacy between the four groups （P〈0.01）. In addition, the clinical efficacy of the sensitization group 3 was better than that of the sensitization group 2 and radiotherapy group （P〈0.01）. The clinical efficacy of the sensitization group 1 was also better than that of radiotherapy group （P 〈 0.05）. The incidence of adverse reactions in the radiotherapy group had no significant dif- ferences with that of sensitization group 1 and 3 （P〉0.05）, but higher than that of sensitization group 2 （P〈0.05）. After treatment, the CRPand CEA levels were significantly different between the four groups （P〈0.01）. The CRP and CEA levels were the lowest in the sensitization group 3 （P〈0.01）, and higher in the sen

关 键 词：放疗 增敏药物 C反应蛋白 肿瘤标志物 

分 类 号：R730.55[医药卫生—肿瘤]